Bristol Myers Squibb has inked a deal to buy San Diego's Turning Point Therapeutics for $4.1 billion in cash, strengthening the pharmaceutical giant's presence in precision cancer treatments.
Shareholders of Turning Point, which went public three years ago at $18 per share, will get $76 per share under terms of the transaction.
While that's a hefty gain from the IPO, it's still well below Turning Point's peak share price of $135.90 in February 2021.